# Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

> **NCT06113913** · PHASE4 · RECRUITING · sponsor: **Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW** · enrollment: 275 (estimated)

## Conditions studied

- Inflammatory Bowel Diseases
- Crohn Disease
- Ulcerative Colitis

## Interventions

- **DRUG:** Infliximab
- **DRUG:** Infliximab
- **DRUG:** Infliximab

## Key facts

- **NCT ID:** NCT06113913
- **Lead sponsor:** Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-09
- **Primary completion:** 2026-05
- **Final completion:** 2026-11
- **Target enrollment:** 275 (ESTIMATED)
- **Last updated:** 2024-07-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06113913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06113913, "Subcutaneous Infliximab After A Previous Intravenous Dose Optimization". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06113913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*